Drug Profile
225 Actinium FPI 1434
Alternative Names: [225Ac]-FPI-1434; FPI-1434; FPX 01Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Centre for Probe Development and Commercialization
- Developer Fusion Pharmaceuticals; Merck & Co
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Colorectal cancer; Lung cancer
Most Recent Events
- 20 Mar 2024 Efficacy and adverse event data from a phase I trial in Solid tumors released by Fusion pharmaceuticals
- 26 Jun 2023 Interim efficacy and adverse events data from a phase I trial in Solid tumors released by Fusion pharmaceuticals
- 28 Feb 2022 FPI 1434 is still in phase I/II trial for Solid tumours (Late-stage disease; Refractory metastatic disease) in Canada, Australia and US (Parenteral, Injection)